eric topol glp 1 The list of conditions for which GLP-1 drugs provide benefit independent of weight loss keeps growing. Add psoriatic arthritis #AAD26 @AADskin The surprising result for a

If you were on 2.4 mg semaglutide and experiencing diminishing returns, you might find that 1.7 mg after a reset produces stronger appetite suppression than 2.4 mg did before

FDA-approved Egrifta (branded Tesamorelin) may be covered for HIV-associated lipodystrophy under specialty pharmacy tiers, but prior authorization requirements are stringent and off-label use for general visceral fat reduction or growth hormone support is denied

The central focus of HDP research has been on maternal pathophysiology and fetal growth failure

Other GLP-1 drugs like Wegovy and Zepbound were developed and tested specifically for obesity treatment with higher doses optimized for weight management outcomes